Business Context and Reporting Period
This Form 8-K Current Report from Revelation Biosciences, Inc. (REVB) covers events occurring on January 3, 2025, and January 6, 2025. The filing addresses the Company's status regarding its listing on The Nasdaq Stock Market following a prior notice of delisting.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on regulatory compliance and listing status.
Material Changes and Listing Status
- Nasdaq Listing Decision: On January 3, 2025, the Nasdaq Hearings Panel granted the Company's request to continue its listing.
- Conditions for Continued Listing:
- Effect a reverse stock split by January 31, 2025.
- Maintain a stock trading price of at least $1.00 for ten consecutive trading days by February 14, 2025.
- Equity Compliance: The Panel confirmed the Company has regained compliance with the Stockholders' Equity Requirement (Listing Rule 5550(b)(1)), resolving a delisting notice issued on August 14, 2024.
- Future Disclosure: Details regarding the reverse stock split ratio and effective date will be disclosed in a subsequent Form 8-K once determined by the Board of Directors.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on business operations. The primary risk identified is the potential failure to meet the specific conditions set by the Nasdaq Hearings Panel (reverse stock split execution and minimum share price maintenance) by the specified deadlines, which could result in delisting.
Investor Verification Checklist
- Verify the announcement of the final reverse stock split ratio and effective date in the upcoming Form 8-K.
- Monitor the daily trading price of REVB to ensure it meets the $1.00 threshold for ten consecutive days by February 14, 2025.
- Confirm the Company's continued compliance with Nasdaq Listing Rule 5550(b)(1) regarding Stockholders' Equity.